Investor Relations

Advancing and building value

Investor Hub


February 24, 2022

Arch Biopartners CEO, Richard Muruve interview, 2022 Venture 50 TMX Recognition

December 15, 2020

Government of Canada Funding to support Phase II Therapeutic Trial

October 15, 2020

Latest Press Releases

Arch Biopartners Engages Independent Trading Group as Market Maker

July 31, 2023 18:02 ET | Source: Arch Biopartners TORONTO, July 31, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced ...

Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial

Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated acute kidney injury (CS-AKI) LSALT peptide targets dipeptidase-1 (DPEP-1), an enzyme known to mediate organ ...

Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide

April 18, 2023 07:10 ET | Source: Arch Biopartners TORONTO, April 18, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), ...
The Press Releases page is the starting place for recent advances, new patents, corporate filings, information for investors and all progress updates on active clinical trials.
  • Browse all of the company’s material news releases.
  • Read the latest releases when they are published here or via email by subscribing to email alerts and news.
Arch Biopartners key stock indicators, price, volume and all historical data.

The Stock Performance page presents the current and historical data for both of the Arch Biopartners securities symbols on the TSX Venture Exchange and the OTCQB Venture Exchange.

The company’s reports and filings include current filings as well as an archive for investors and the public for research and review:

View the complete Arch Biopartners Inc. filings archives at the SEDAR website here .

Investor relations contact information, auditor and transfer agent.
Investment Analysts covering Arch Biopartners.
Contact Arch Biopartners
Stay connected!

Subscribe for email updates

Get email alerts when news is published
Please check the options for Investor News and Science Updates to receive additional information about events and publications

Press Release Archives